

Breast:

Adjuvant

AFT-05/BIG 14-03 PALLAS- A Randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER-2) negative early breast cancer.

NRG BR003-A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer.

Metastatic:

ACCRU RU0112011-A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer.

ECOG-ACRIN E2112-A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer.

Cancer Control

None

GYN Studies:

Ovary

GOG 0225- Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

NRG GY003- Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer.

Colon:

Adjuvant

None

Registry

NSABP MPR-1-Patient Registry and Biospecimen Profiling Registry for Patients with Metastatic Colorectal Cancer who have had tumor resection

Pancreatic:

Metastatic

SWOG S1313- A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma.

Prostate:

Metastatic:

ALLIANCE A031201- Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer.

Lung:

Adjuvant:

Alliance A151216- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Alliance A081105- Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

ECOG-ACRIN E4512- A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

ECOG-ACRIN EA5142- A Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

NSCL Metastatic:

Amgen 20070782- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500mcg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy

BMS CheckMate 370- A Master Protocol of Phase I/II Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-Line Treatment Alone or in Combination with Standard of Care Therapies.

SWOG S1400- Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Lung-Map)

S1400B: PK+, GDC-0032

S1400C: Cell cycle gene alteration +, palbociclib

S1400D: FGFR+, AZD4547

S1400I: Non-Match – Nivolumab/Ipilimumab vs Nivolumab

Lilly NSCLC (Non-Squamous) Survey- Patient and Oncologist Decision Making Related to Maintenance Treatment for Advanced Non-Small Cell Lung Cancer in the United States: Patient Survey.

Lymphoma: None

Multiple Myeloma:

Treatment:

Maia 54767414MMY3008- A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy.

Registry:

UNC LCCC 0916- UNC Carolina Senior Registry